RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma

Cell

Volumn 161, Issue 6, 2015, Pages 1345-1360

  Whittle, Martin C ^a   Izeradjene, Kamel ^a   Geetha Rani, P ^a   Feng, Libing ^a   Carlson, Markus A ^a   DelGiorno, Kathleen E ^a   Wood, Laura D ^b   Goggins, Michael ^b   Hruban, Ralph H ^b   Chang, Amy E ^a   Calses, Philamer ^a   Thorsen, Shelley M ^a   Hingorani, Sunil R ^a,c  

^a USA   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CELL DIVISION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DPC4 GENE; GENE; GENE EXPRESSION; GENE MUTATION; GENETICALLY ENGINEERED MOUSE STRAIN; HETEROZYGOSITY; HETEROZYGOSITY LOSS; METASTASIS; MOUSE; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SECRETION; RUNX3 GENE; SMAD4 GENE; TUMOR INVASION; TUMOR SUPPRESSOR GENE; ANIMAL; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY;

KRAS2 PROTEIN, MOUSE; PROTEIN P21; RUNX3 PROTEIN, HUMAN; SMAD4 PROTEIN; SMAD4 PROTEIN, MOUSE; TRANSCRIPTION FACTOR RUNX3;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DISEASE MODELS, ANIMAL; GENES, P53; HUMANS; MICE; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); SMAD4 PROTEIN;

EID: 84930475656     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2015.04.048     Document Type: Article

References (41)

1. Aguirre, A.J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D.A., Horner, J., Redston, M.S., and DePinho, R.A. (2003). Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17, 3112-3126.
2. Allison, D.C., Piantadosi, S., Hruban, R.H., Dooley, W.C., Fishman, E.K., Yeo, C.J., Lillemoe, K.D., Pitt, H.A., Lin, P., and Cameron, J.L. (1998). DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J. Surg. Oncol. 67, 151-159.
3. Armstrong, T., Packham, G., Murphy, L.B., Bateman, A.C., Conti, J.A., Fine, D.R., Johnson, C.D., Benyon, R.C., and Iredale, J.P. (2004). Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 10, 7427-7437.
4. Bae, S.C., and Choi, J.K. (2004). Tumor suppressor activity of RUNX3. Oncogene 23, 4336-4340.
5. Bardeesy, N., Aguirre, A.J., Chu, G.C., Cheng, K.H., Lopez, L.V., Hezel, A.F., Feng, B., Brennan, C., Weissleder, R., Mahmood, U., et al. (2006). Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc. Natl. Acad. Sci. USA 103, 5947-5952.
6. Blyth, K., Cameron, E.R., and Neil, J.C. (2005). The RUNX genes: gain or loss of function in cancer. Nat. Rev. Cancer 5, 376-387.
7. Bonaldo, P., Russo, V., Bucciotti, F., Doliana, R., and Colombatti, A. (1990). Structural and functional features of the alpha 3 chain indicate a bridging role for chicken collagen VI in connective tissues. Biochemistry 29, 1245-1254.
8. Chi, X.Z., Yang, J.O., Lee, K.Y., Ito, K., Sakakura, C., Li, Q.L., Kim, H.R., Cha, E.J., Lee, Y.H., Kaneda, A., et al. (2005). RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor beta-activated SMAD. Mol. Cell. Biol. 25, 8097-8107.
9. Chuang, L.S., and Ito, Y. (2010). RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 29, 2605-2615.
10. Crippa, S., Salvia, R., Warshaw, A.L., Domínguez, I., Bassi, C., Falconi, M., Thayer, S.P., Zamboni, G., Lauwers, G.Y., Mino-Kenudson, M., Capelli, P., Pederzoli, P., and Castillo, C.F. (2008). Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann. Surg. 247, 571-579.
11. Deer, E.L., González-Hernández, J., Coursen, J.D., Shea, J.E., Ngatia, J., Scaife, C.L., Firpo, M.A., and Mulvihill, S.J. (2010). Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39, 425-435.
12. Fidler, I.J. (1973). The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Eur. J. Cancer 9, 223-227.
13. Friedl, P., and Alexander, S. (2011). Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147, 992-1009.
14. Gillen, S., Schuster, T., Meyer Zum Büschenfelde, C., Friess, H., and Kleeff, J. (2010). Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 7, e1000267.
15. Hidalgo, M. (2010). Pancreatic cancer. N. Engl. J. Med. 362, 1605-1617.
16. Hingorani, S.R., Petricoin, E.F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A., et al. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450.
17. Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban, R.H., Rustgi, A.K., Chang, S., and Tuveson, D.A. (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483.
18. Hruban, R.H., Adsay, N.V., Albores-Saavedra, J., Compton, C., Garrett, E.S., Goodman, S.N., Kern, S.E., Klimstra, D.S., Klöppel, G., Longnecker, D.S., et al. (2001). Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 25, 579-586.
19. Iacobuzio-Donahue, C.A., Wilentz, R.E., Argani, P., Yeo, C.J., Cameron, J.L., Kern, S.E., and Hruban, R.H. (2000). Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am. J. Surg. Pathol. 24, 1544-1548.
20. Iacobuzio-Donahue, C.A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C.M., Vilardell, F., Wang, Z., Keller, J.W., Banerjee, P., et al. (2009). DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J. Clin. Oncol. 27, 1806-1813.
21. Iacobuzio-Donahue, C.A., Velculescu, V.E., Wolfgang, C.L., and Hruban, R.H. (2012). Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin. Cancer Res. 18, 4257-4265.
22. Ito, K., Inoue, K.I., Bae, S.C., and Ito, Y. (2009). Runx3 expression in gastrointestinal tract epithelium: resolving the controversy. Oncogene 28, 1379-1384.
23. Izeradjene, K., Combs, C., Best, M., Gopinathan, A., Wagner, A., Grady, W.M., Deng, C.X., Hruban, R.H., Adsay, N.V., Tuveson, D.A., and Hingorani, S.R. (2007). Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11, 229-243.
24. Katz, M.H., Fleming, J.B., Lee, J.E., and Pisters, P.W. (2010). Current status of adjuvant therapy for pancreatic cancer. Oncologist 15, 1205-1213.
25. Lee, Y.S., Lee, J.W., Jang, J.W., Chi, X.Z., Kim, J.H., Li, Y.H., Kim, M.K., Kim, D.M., Choi, B.S., Kim, E.G., et al. (2013). Run× 3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell 24, 603-616.
26. Levanon, D., Brenner, O., Negreanu, V., Bettoun, D., Woolf, E., Eilam, R., Lotem, J., Gat, U., Otto, F., Speck, N., and Groner, Y. (2001). Spatial and temporal expression pattern of Run× 3 (Aml2) and Run× 1 (Aml1) indicates non-redundant functions during mouse embryogenesis. Mech. Dev. 109, 413-417.
27. Levanon, D., Bernstein, Y., Negreanu, V., Bone, K.R., Pozner, A., Eilam, R., Lotem, J., Brenner, O., and Groner, Y. (2011). Absence of Run× 3 expression in normal gastrointestinal epithelium calls into question its tumour suppressor function. EMBO Mol. Med. 3, 593-604.
28. Li, Q.L., Ito, K., Sakakura, C., Fukamachi, H., Inoue, Ki., Chi, X.Z., Lee, K.Y., Nomura, S., Lee, C.W., Han, S.B., et al. (2002). Causal relationship between the loss of RUN× 3 expression and gastric cancer. Cell 109, 113-124.
29. Lunardi, S., Muschel, R.J., and Brunner, T.B (2014). The stromal compartments in pancreatic cancer: are there any therapeutic targets? Cancer Lett. 343, 147-155.
30. Pérez-Mancera, P.A., Guerra, C., Barbacid, M., and Tuveson, D.A. (2012). What we have learned about pancreatic cancer from mouse models. Gastroenterology 142, 1079-1092.
31. Poruk, K.E., Firpo, M.A., Scaife, C.L., Adler, D.G., Emerson, L.L., Boucher, K.M., and Mulvihill, S.J. (2013). Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 42, 193-197.
32. Psaila, B., and Lyden, D. (2009). The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 9, 285-293.
33. Scarpa, A., Capelli, P., Mukai, K., Zamboni, G., Oda, T., Iacono, C., and Hirohashi, S. (1993). Pancreatic adenocarcinomas frequently show p53 gene mutations. Am. J. Pathol. 142, 1534-1543.
34. Schreiber, F.S., Deramaudt, T.B., Brunner, T.B., Boretti, M.I., Gooch, K.J., Stoffers, D.A., Bernhard, E.J., and Rustgi, A.K. (2004). Successful growth and characterization of mouse pancreatic ductal cells: functional properties of the Ki-RAS(G12V) oncogene. Gastroenterology 127, 250-260.
35. Stromnes, I.M., DelGiorno, K.E., Greenberg, P.D., and Hingorani, S.R. (2014). Stromal reengineering to treat pancreas cancer. Carcinogenesis 35, 1451-1460.
36. Tarin, D., Thompson, E.W., and Newgreen, D.F. (2005). The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 65, 5996-6000, discussion, 6000-5991.
37. Wilentz, R.E., Iacobuzio-Donahue, C.A., Argani, P., McCarthy, D.M., Parsons, J.L., Yeo, C.J., Kern, S.E., and Hruban, R.H. (2000). Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 60, 2002-2006.
38. Yachida, S., White, C.M., Naito, Y., Zhong, Y., Brosnan, J.A., Macgregor-Das, A.M., Morgan, R.A., Saunders, T., Laheru, D.A., Herman, J.M., et al. (2012). Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin. Cancer Res. 18, 6339-6347.
39. Yamada, C., Ozaki, T., Ando, K., Suenaga, Y., Inoue, K., Ito, Y., Okoshi, R., Kageyama, H., Kimura, H., Miyazaki, M., and Nakagawara, A. (2010). RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53. J. Biol. Chem. 285, 16693-16703.
40. Yarmus, M., Woolf, E., Bernstein, Y., Fainaru, O., Negreanu, V., Levanon, D., and Groner, Y. (2006). Groucho/transducin-like Enhancer-of-split (TLE)-dependent and-independent transcriptional regulation by Runx3. Proc. Natl. Acad. Sci. USA 103, 7384-7389.
41. Yu, K.H., Barry, C.G., Austin, D., Busch, C.M., Sangar, V., Rustgi, A.K., and Blair, I.A. (2009). Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery. J. Proteome Res. 8, 1565-1576.